Five-year-old French biotech Cerenis Therapeutics SA pulled in its third major venture round, adding €40 million (US$51.9 million) in Series C funding to advance its lead program, HDL-mimetic CER-001, into Phase II testing in cardiovascular disease. (BioWorld International)
Rumors of a takeover offer by Sanofi-Aventis SA sent shares of Genzyme Corp. up 15.4 percent Friday, only days after the Cambridge, Mass.-based biotech reported that it was finally getting back on track following last year's manufacturing debacle. (BioWorld Today)
